MICHAEL V. DRAKE IS APPOINTED TO THE BOARD OF DIRECTORS BY AMGEN

Published on: 02 August 2022
1659557851525

Amgen today announced the immediate appointment of Michael V. Drake, M.D. to its Board of Directors. Dr. Drake will also serve on the Corporate Responsibility and Compliance Committee of the Board, as well as the Governance and Nominating Committee.

Following the appointment of Dr. Drake, the Board will be composed of 13 directors, 12 of whom are independent.

Dr. Drake is president of the University of California, a system of 10 campuses, five medical centers and three nationally affiliated labs that serves more than 280,000 students and employs 230,000 faculty and staff.

"Michael is an accomplished physician and leader who heads one of the largest, most diverse and well-respected academic institutions in the world,"

said Robert A. Bradway, chairman and chief executive officer of Amgen.

"He will add tremendous value to Amgen given his extensive medical, scientific and leadership experience as we continue to drive innovation to address serious illness."

Dr. Drake served as president of The Ohio State University (OSU) from 2014 to 2020, during which the university saw all-time highs in applications, graduation rates, industry-sponsored research and academic preparation and diversity of incoming classes.  Prior to OSU, he served for nine years as chancellor of the University of California, Irvine and was UC Irvine's systemwide vice president for health affairs from 2000 to 2005.

Dr. Drake received his undergraduate degree from Stanford University and his medical doctorate from the University of California, San Francisco. 

About Amgen: Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients worldwide and is developing a pipeline of medicines with breakaway potential.  

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index.  In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

Source: Amgen news

Share:
esg
esg
esg
esg
More from Amgen Inc.
AMGEN releases its first GREEN BOND to advance ESG objectives
AMGEN releases its first GREEN BOND to advance ESG objectives
Amgen Awarded for ESG Performance Excellence
Amgen Awarded for ESG Performance Excellence
Amgen Selected To The Dow Jones Sustainability World Index For The Eighth Year Running
Amgen Selected To The Dow Jones Sustainability World Index For The Eighth Year Running